Transition report pursuant to Rule 13a-10 or 15d-10

Statements of Stockholders??? Equity (Deficit)

v3.22.1
Statements of Stockholders’ Equity (Deficit) - USD ($)
$ in Thousands
Series A
Preferred Stock
Series B
Preferred Stock
Series C
Preferred Stock
Common Stock
Additional Paid-in Capital
Accumulated Deficit
Total
Balance at Mar. 31, 2020 $ 1 $ 9,487 $ (16,448) $ (6,960)
Balance (in Shares) at Mar. 31, 2020       5,774,778      
Issuance of common stock and warrants, net of fees   20,389   20,389
Issuance of common stock and warrants, net of fees (in Shares)       5,235,833      
Issuance of common stock in satisfaction of accounts payable 122 122
Issuance of common stock in satisfaction of accounts payable (in Shares)       54,149      
Issuance of common stock in connection with notes payable 1,134 1,134
Issuance of common stock in connection with notes payable (in Shares)       366,667      
Issuance of common stock and preferred stock in connection with conversion of notes 23,715 23,715
Issuance of common stock and preferred stock in connection with conversion of notes (in Shares) 251 1,443 500,756 2,830,079      
Repurchased beneficial conversion feature in connection with conversion of notes payable (6,647) (6,647)
Issuance of common stock warrants in connection with note exchange agreements 4,918 4,918
Issuance of common stock warrants 263   263
Exercise of common stock warrants   180   180
Exercise of common stock warrants (in Shares)       316,421      
Beneficial conversion feature in connection with notes payable 619   619
Issuance of common stock to consultants   305   305
Issuance of common stock to consultants (in Shares)       108,792      
Stock-based compensation   14,126   14,126
Stock-based compensation (in Shares)       2,371,428      
Stock option exercises    
Stock option exercises (in Shares)       25,000      
Canceled restricted stock awards    
Canceled restricted stock awards (in Shares)       (2,060,000)      
Common stock repurchased and subsequently canceled   (450)   (450)
Common stock repurchased and subsequently canceled (in Shares)       (166,667)      
Reclassification of warrant liabilities 5,627 5,627
Net income (loss) (40,755) (40,755)
Balance at Mar. 31, 2021 $ 1 73,789 (57,203) 16,587
Balance (in Shares) at Mar. 31, 2021 251 1,443 500,756 14,856,480      
Issuance of common stock in connection with consulting agreements 244 244
Issuance of common stock in connection with consulting agreements (in Shares)       64,261      
Restricted stock awards exchanged for restricted stock units
Restricted stock awards exchanged for restricted stock units (in Shares)       (800,000)      
Stock-based compensation 8,458 8,458
Stock option exercises 186 186
Stock option exercises (in Shares)       409,385      
Net income (loss) (16,487) (16,487)
Balance at Dec. 31, 2021 $ 1 $ 82,677 $ (73,690) $ 8,988
Balance (in Shares) at Dec. 31, 2021 251 1,443 500,756 14,530,126